Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.
Stage IB-IIIA non-small cell cancer patients who after complete resection.
≥18 years.
Two-round MRD tests confirm landmark undetectable MRD.
Expected survival ≥12 weeks.
Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy.
Patients with a history of other malignancies in the past 5 years.
Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).
Stage IB-IIIA NSCLC patients who after complete resection and undetectable landmark MRD.
Cohort
Prospective
Molecular residual disease test
Diagnostic testOncoMRD Lung
Two-years disease free survival rates for patients with longitudinal undetectable MRD
The 2-year DFS rate of patients who maintain 2-years undetectable MRD.
Two-years disease free survival rates for patients with six months longitudinal undetectable MRD
The 2-year DFS rate of patients who maintain 6-months undetectable MRD.
Two-years disease free survival rates for patients with 12-months longitudinal undetectable MRD
The 2-year DFS rate of patients who maintain 12-months undetectable MRD.
Two-years disease free survival rates for patients with 18-months longitudinal undetectable MRD
The 2-year DFS rate of patients who maintain 18-months undetectable MRD.
Two-years event-free survival rates for enrolled patients in two years
The events are defined as disease recurrence or detectable MRD.
Click on the lead sponsor to view all of their trials.
